It was announced today that the phase I/II trial of MDV3100 demonstrated positive results. MDV3100 is a novel triple-acting oral androgen receptor antagonist, the common antagonist most of us are familiar with today is Casodex. These results were published in the online April 15 version of The Lancet. […]
As you already know, I am very interested and a strong believer in the future of immunologic therapy. I have written extensively about Provenge and last week I told you about a phase I clinical trial of a Vaccine Therapy for men with progressive stage D0 (non-metastatic) prostate cancer. (http://advancedprostatecancer.net/?p=1419). I want to now let [...]
Researchers at the Department of Urology, Centre Hospitalier Universitaire du Québec (CHUQ), Quebec, Canada evaluated the rate and duration of prostate-specific antigen (PSA) response to high-dose bicalutamide (150 mg) in men with non-metastatic castration-resistant prostate cancer (nmHRPC) as well as its impact on the duration of metastasis-free survival. They concluded that high dose bicalutamide is [...]
The continuing search for effective treatments for men with hormone refractory prostate cancer (HRPC) has been a long and not very successful story. To date, under scientific conditions, the only chemotherapy which has demonstrated any survival benefit for men with prostate cancer has been docetaxel with prednisone. However, the survival benefit is very limited, only [...]
Thanks to Kathy Meade, I just viewed an exceptional video about advanced prostate cancer. It also includes information on bone health, screening, research, the need for funding and the history of prostate cancer treatment. All advocates and men with prostate cancer should learn something by watching the video. The following is the link: http://www.itvisus.com/programs/hbhm/index.asp#ooid=Iza2VhMTqn-tHgaxfstDRMBJ 1b12EW7i [...]
According to a new position paper from the North American Menopause Society (NAMS), despite all the new drugs that are available, diet and lifestyle should remain the first osteoporosis management tool. Only after diet and lifestyle has failed should any of the newly approved treatment options to prevent osteoporosis be considered. […]
In yesterday’s post, Provenge, Its Future & A Clinical Trail Alternative for Men with Hormone Dependent Prostate Cancer, I said that I attempted to get into a vaccine trial, but was rejected because I have a history of an autoimmune disease and I have had evidence of some lymph node involvement (stage D1). I want [...]
I have received a number of e-mails from men who are both frustrated that Provenge is not yet approved and who are frustrated that even when approved they will not qualify to get the treatment. I understand the frustration and feel the same way. The first question is will the FDA approve Provenge? Only time [...]
From: Carolyn Messner , DSW, MSW Director of Education and Training CancerCare Getting a good night’s sleep is important for everyone. However, for cancer survivors, sleep can sometimes be challenging. On Tuesday, April 13th, CancerCare, in collaboration with the National Cancer Institute, LIVESTRONG, Intercultural Cancer Council, Living Beyond Breast Cancer and National Coalition for Cancer [...]
I have just read a report from Mike Scott of a 64-year-old Croatian man who was recently diagnosed with advanced prostate cancer. His PSA was 21,380 ng/ml! Yes, I said a PSA of 21,380. Now, hold on to your seats for even more intriguing information. According to the report this man has never experienced any [...]
